CD Pharma India Pvt Ltd (CDPIL), a wholly owned subsidiary of VSL Pharmaceuticals Inc, is expanding its clinical trial operations in India. Currently, the company has initiated around ten clinical trials across centres like AIMS, MAMS, ETC.
The company has started clinical trials for VSL #3 and they have concluded trials with more 200 infants for treating rotavirus induced diarrhoea. The results of these trials are being collated for publication and are expected to be ready by end of 2007.
Currently, around ten clinical trials are on ongoing, using different proprietary probiotic preparations, across indications like Ulcerative colitis, Microscopic colitis, Chemotherapy and/or radiotherapy induced Oral Mucositis in Head and Neck Cancer patients, Chronic Periodontitis.
Speaking to Pharmabiz, Kanwaldeep Chadha, country manager of CD Pharma India and director Asia Pacific, said, "Currently, the clinical trial are ongoing in different indications VSL #3 and Florisa, a brand of vaginal tablets developed for vaginal infections such as bacterial vaginosis. Our products and technology have been developed with distinct mechanism of action claimed due to different enzymes present in different strains of bacteria. All the products and technologies are patent protected with patents already extended to India as well. We have already been granted two patents in India and the balance are in the pipeline.
The company is developing product and technologies from Lactic Acid Bacteria (probiotics). At present company is working on anti-microbial tablet and VSL #3. The company is developing anti-microbial tablet, for the prevention of the HIV / HSV infections and likely to introduce the same in India early next year. In the same year company will launch its VSL #3 probiotic in the Indian market, for the treatment of gastroenterology and lever.